Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Revolution Medicines' Rasonque Approved by FDA for Metastatic Pancreatic Cancer

Revolution Medicines' Rasonque Approved by FDA for Metastatic Pancreatic Cancer

MT newswireMT newswire2026/08/26 16:58
12:58 PM EDT, 08/26/2026 (MT Newswires) -- Revolution Medicines' (RVMD) Rasonque (daraxonrasib) has been approved for the treatment of metastatic pancreatic cancer, the US Food and Drug Administration said Wednesday. The approval is for treatment of adults with metastatic pancreatic adenocarcinoma, who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy, the FDA said. The most common side effects of the drug are rash, diarrhea, stomatitis, nausea, fatigue, among others, according to a statement. Price: 211.82, Change: +0.44, Percent Change: +0.21
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!